Unless Teva wants to launch at risk (which presumes they don't have much respect for this lawsuit) it is hard to see an interpration of this that is negative for MNTA vis a vie the near-term prospects of t-enoxaparin approval.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.